openPR Logo
Press release

Download Global B Cell Lymphoma Market and Clinical Pipeline Insight 2022 Report

09-14-2017 09:37 AM CET | Health & Medicine

Press release from: Kuick Resarch

Download Global B Cell Lymphoma Market and Clinical Pipeline

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink:https://www.kuickresearch.com/report-global-b-cell-lymphoma-market-and-clinical-pipeline-insight-2022.php

1. Introduction to B Cell Lymphoma
1.1 Outline
1.1.1 Non-Hodgkin’s Lymphoma
1.1.2 Hodgkin’s Lymphoma
1.2 Classification of the B Cell lymphoma
1.2.1 Diffuse Large B Cell Lymphoma
1.2.2 Follicular Lymphoma
1.2.3 Mantle Cell Lymphoma
1.2.4 Burkitt Lymphoma
1.3 Stages of B Cell Lymphoma

2. Role of B Cell Receptor for Lymphoma Development
2.1 Diffuse Large B Cell Lymphoma
2.2 Mantle Cell Lymphoma
2.3 Burkitt Lymphoma

3. Non-Hodgkin Lymphoma Risk Factors
3.1 Overview of Risk Factors
3.1.1 Infections
3.1.2 Weakened Immune System
3.1.3 Exposure to Radiation
3.1.4 Exposure to Chemicals
3.2 Causes of Non-Hodgkin Lymphoma

4. Strategies for B Cell Lymphoma Targeting Therapies
4.1 Current Strategies
4.1.1 Bruton’s Tyrosine Kinase (BTK)
4.1.2 Phosphoinositide 3-Kinase anddelta; (PI3Ks)
4.1.3 Spleen Tyrosine Kinase (SYK)
4.2 Next Generation Strategies for the Vaccine Therapy
4.2.1 Membrane Proteoliposomal Vaccine
4.2.2 Cytotoxic Therapies

5. Diagnosis of B Cell Lymphoma
5.1 Traditional Methods of Detection
5.1.1 Biopsy Method
5.1.2 Flow Cytometry
5.1.3 Molecular Genetic Tests
5.1.4 Positron Emission Tomography (PET) Scan
5.2 New Insights for Diagnosis of B Cell Lymphoma
5.2.1 Genomic Studies in the Diagnosis
5.2.2 Next Generation Sequencing
5.3 Biomarker in B Cell Malignancies
5.3.1 MicroRNA-155
5.3.2 B Cell Markers

6. Approaches for the Treatment B Cell Lymphoma
6.1 Chemotherapy
6.2 Radiation Therapy

7. Targeted Therapy Drugs for B Cell Lymphoma
7.1 Proteasome Inhibitors
7.2 Anti-CD22 Antibody Epratuzumab
7.3 Immunomodulators
7.4 Fostamatinib Disodium (Syk Inhibitor)
7.5 Membrane Target of Rapamycin (mTOR)

8. Global B Cell Lymphoma Market Overview
8.1 Current Scenario
8.2 Prevalence
8.3 B Cell Lymphoma Clinical Pipeline Overview

9. Global B Cell Lymphoma Market Dynamics
9.1 Accelerative Parameters
9.2 Challenges to the Market Growth

10. Global B Cell Lymphoma Market Future Scenario

11. Global B Cell Lymphoma Clinical Pipeline by Company and Phase
11.1 Research
11.2 Preclinical
11.3 Clinical
11.4 Phase-I
11.5 Phase-I/II
11.6 Phase-II
11.7 Phase-II/III
11.8 Phase-III
11.9 Preregistration
11.10 Registered

12. Marketed B Cell Lymphoma Clinical Insight
12.1 Rituximab (MabThera and Rituxan)
12.2 Rituximab Biosimilar (Novex)
12.3 Rituximab Biosimilar (Maball)

13. Competitive Landscape
13.1 Abbott Laboratories
13.2 Biogen Idec
13.3 Celgene Corporation
13.4 Genmab
13.5 Hetero Drugs
13.6 ImmunoGen
13.7 Incyte Corporation
13.8 mAbxience
13.9 Merck
13.10 Millennium Pharmaceuticals
13.11 Ono Pharmaceutical
13.12 Sandoz
13.13 Seattle Genetics
13.14 Xencor

Figure 1-1: Types of B Cell Lymphoma
Figure 1-2: B Cell Lymphoma Stages
Figure 2-1: B Cell Receptor in Diffuse Large B Cell Lymphoma
Figure 2-2: B Cell Receptor Signaling Pathway in Mantle Cell Lymphoma
Figure 3-1: Risk Factors Associated with B Cell Lymphoma
Figure 4-1: Bruton’s Tyrosine Kinase Pathway for Targeting
Figure 4-2: Phosphoinositide 3-Kinase anddelta; as Targeting Therapy
Figure 4-3: Spleen Tyrosine Kinase for Targeting
Figure 5-1: Traditional Methods for Diagnosis of B Cell Lymphoma
Figure 5-2: Noval Techniques for Detection
Figure 6-1: Approaches for the Treatment of B Cell Lymphoma
Figure 8-1: Global - Non-Hodgkin Lymphoma Market (US$ Billion), 2016 - 2022
Figure 8-2: Global - Hodgkin Lymphoma Market (US$ Million), 2016 - 2022
Figure 8-3: Survival Rate of Non-Hodgkin Lymphoma, % (5, 10, 15 Years)
Figure 8-4: Early Stage and Advance Stage Survival Rate, %
Figure 8-5: Estimated Cases of Non-Hodgkin Lymphoma, 100,000 Persons
Figure 8-6: US - B Cell Lymphoma Incidence
Figure 8-7: UK - Diagnosed Cases in Males and Females
Figure 8-8: UK - Mortality Cases in Males and Females
Figure 8-9: India - Incidence Rate in Males and Females
Figure 8-10: Global - B Cell Lymphoma Clinical Pipeline by Phase (%), 2017 till 2022
Figure 8-11: Global -B Cell Lymphoma Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 8-12: Global - Discontinued and Suspended B Cell Lymphoma Drugs in Clinical Pipeline (%), 2017 till 2022
Figure 8-13: Global - Discontinued and Suspended B Cell Lymphoma Drugs in Clinical Pipeline (Number), 2017 till 2022
Figure 9-1: Market Drivers of B cell Lymphoma
Figure 9-2: Challenges to the Growth of the Market

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Kuick Research
New Delhi - 110001
India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Download Global B Cell Lymphoma Market and Clinical Pipeline Insight 2022 Report here

News-ID: 716110 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Lymphoma

Daratumumab Market Precise Analysis , Forecast || key Players- Multiple Myeloma, …
Looking at the current market trends as well as the promising demand status of the “Daratumumab Market”, it can be projected that the future years will bring out positive outcomes. This research report added by Market Research Hub (MRH) on its online portal delivers clear insight about the changing tendencies across the global market. Readers can gather prime facets connected to the target market which includes product, end-use and application;
Overview Of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Re …
Researchmoz added Most up-to-date research on "Overview Of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Review, H2, 2017" to its huge collection of research reports. GlobalData's clinical trial report, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Global Clinical Trials Review, H2, 2017" provides an overview of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) clinical trials scenario. This report provides top line data relating to the clinical trials on Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma). Report
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape. Hodgkin disease is a cancer of the lymphatic system. It
Pipeline Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Market Review, H2 2017
"The Report Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2017, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) (Oncology) pipeline landscape. Hodgkin disease is a cancer of the lymphatic system. It
T Cell Lymphoma Market T Cell Lymphoma Clinical Pipeline Report
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. T-Cell Lymphoma Market Analysis 2. Mechanism of T-Cell Lymphoma Therapeutics 3. T-Cell Lymphoma Drug Market Overview 3.1 Current Market Scenario 3.2 T Cell Lymphoma Clinical Pipeline Overview 4. T-Cell Lymphoma Drug Market Dynamics 4.1 Favorable Market Parameters 4.2 Commercialization Challenges 5. T-Cell Lymphoma Drug Market Future Prospects 6. T-Cell Lymphoma Drug Clinical Pipeline By Company
B Cell Lymphoma Market B Cell Lymphoma Clinical Pipeline Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to B Cell Lymphoma 1.1 Outline 1.1.1 Non-Hodgkin’s Lymphoma 1.1.2 Hodgkin’s Lymphoma 1.2 Classification of the B Cell lymphoma 1.2.1 Diffuse Large B Cell Lymphoma 1.2.2 Follicular Lymphoma 1.2.3 Mantle Cell Lymphoma 1.2.4 Burkitt Lymphoma 1.3 Stages of